115 related articles for article (PubMed ID: 38307818)
41. Regional differences in clear cell metastatic renal cell carcinoma patients across the USA.
Scheipner L; Tappero S; Piccinelli ML; Barletta F; Garcia CC; Incesu RB; Morra S; Baudo A; Tian Z; Saad F; Shariat SF; Terrone C; De Cobelli O; Briganti A; Chun FKH; Tilki D; Longo N; Carmignani L; Pichler M; Hutterer G; Ahyai S; Karakiewicz PI
World J Urol; 2023 Nov; 41(11):2991-3000. PubMed ID: 37755519
[TBL] [Abstract][Full Text] [Related]
42. Survival of patients with clear cell renal carcinoma according to number and location of organ-specific metastatic sites.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Baudo A; Tian Z; Parodi S; Dell'Oglio P; Briganti A; de Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Carmignani L; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Urol Oncol; 2024 Jan; 42(1):22.e23-22.e31. PubMed ID: 37775340
[TBL] [Abstract][Full Text] [Related]
43. Shifting role of cytoreductive nephrectomy according to type of systemic therapy: A nationwide cohort study.
Choi SY; Ha MS; Lee JW; Kim JH; Kim JH; Chi BH; Kim JW; Chang IH; Kim TH; Myung SC
Asian J Surg; 2023 Jan; 46(1):328-336. PubMed ID: 35450758
[TBL] [Abstract][Full Text] [Related]
44. Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma.
Panunzio A; Sorce G; Tappero S; Hohenhorst L; Garcia CC; Piccinelli M; Tian Z; Tafuri A; De Cobelli O; Chun FKH; Tilki D; Terrone C; Briganti A; Kapoor A; Saad F; Shariat SF; Cerruto MA; Antonelli A; Karakiewicz PI
Cancer Epidemiol; 2023 Feb; 82():102297. PubMed ID: 36401949
[TBL] [Abstract][Full Text] [Related]
45. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer.
Bandini M; Marchioni M; Preisser F; Zaffuto E; Tian Z; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
World J Urol; 2018 Sep; 36(9):1399-1407. PubMed ID: 29717358
[TBL] [Abstract][Full Text] [Related]
46. Results of a comparative study analyzing octogenarians with renal cell carcinoma in a competing risk analysis with patients in the seventh decade of life.
May M; Cindolo L; Zigeuner R; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Truss M; Dalpiaz O; Wolff I; Feciche B; Fenske F; Pichler M; Schips L; Figenshau RS; Madison K; Sánchez-Chapado M; Santiago Martin Mdel C; Salzano L; Lotrecchiano G; Waidelich R; Stief C; Sountoulides P; Brookman-May S; ;
Urol Oncol; 2014 Nov; 32(8):1252-8. PubMed ID: 25129141
[TBL] [Abstract][Full Text] [Related]
47. Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study.
Eminaga O; Akbarov I; Wille S; Engelmann U
Int Urol Nephrol; 2015 Oct; 47(10):1653-63. PubMed ID: 26329746
[TBL] [Abstract][Full Text] [Related]
48. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database.
Lughezzani G; Sun M; Perrotte P; Shariat SF; Jeldres C; Budäus L; Latour M; Widmer H; Duclos A; Bénard F; McCormack M; Montorsi F; Karakiewicz PI
Urology; 2010 Feb; 75(2):321-7. PubMed ID: 19962727
[TBL] [Abstract][Full Text] [Related]
49. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities.
Sun M; Bianchi M; Trinh QD; Hansen J; Abdollah F; Hanna N; Tian Z; Shariat SF; Montorsi F; Perrotte P; Karakiewicz PI
BJU Int; 2013 Jan; 111(1):67-73. PubMed ID: 22612472
[TBL] [Abstract][Full Text] [Related]
50. Other-Cause Mortality, According to Partial vs. Radical Nephrectomy: Age and Stage Analyses.
Baudo A; Incesu RB; Morra S; Scheipner L; Jannello LMI; de Angelis M; Siech C; Tian Z; Acquati P; Tilki D; Longo N; Ahyai S; de Cobelli O; Briganti A; Chun FKH; Saad F; Shariat SF; Carmignani L; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):181-188. PubMed ID: 38042729
[TBL] [Abstract][Full Text] [Related]
51. Radical Versus Partial Nephrectomy for cT1 Renal Cell Carcinoma.
Gershman B; Thompson RH; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
Eur Urol; 2018 Dec; 74(6):825-832. PubMed ID: 30262341
[TBL] [Abstract][Full Text] [Related]
52. Differences in other-cause mortality in metastatic renal cell carcinoma according to partial vs. radical nephrectomy and age: A propensity score matched study.
Siech C; Incesu RB; Morra S; Scheipner L; Baudo A; Jannello LMI; de Angelis M; Goyal JA; Tian Z; Saad F; Shariat SF; Tilki D; Longo N; Carmignani L; de Cobelli O; Ahyai S; Briganti A; Mandel P; Kluth LA; Chun FKH; Karakiewicz PI
Surg Oncol; 2024 Apr; 53():102047. PubMed ID: 38359547
[TBL] [Abstract][Full Text] [Related]
53. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
54. Assessment of other-cause mortality in localized renal cell carcinoma patients within 15 years: A population-based analysis.
Pecoraro A; Knipper S; Palumbo C; Rosiello G; Luzzago S; Tian Z; Shariat SF; Saad F; Briganti A; Fiori C; Porpiglia F; Karakiewicz PI
J Surg Oncol; 2020 Dec; 122(7):1506-1513. PubMed ID: 32812284
[TBL] [Abstract][Full Text] [Related]
55. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
[TBL] [Abstract][Full Text] [Related]
56. Married Status Affects Rates of Treatment and Mortality in Male and Female Renal Cell Carcinoma Patients Across all Stages.
Siech C; Morra S; Scheipner L; Baudo A; Jannello LMI; de Angelis M; Goyal JA; Tian Z; Saad F; Shariat SF; Longo N; Carmignani L; de Cobelli O; Ahyai S; Briganti A; Mandel P; Kluth LA; Chun FKH; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):593-598. PubMed ID: 38369387
[TBL] [Abstract][Full Text] [Related]
57. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Graham J; Wells JC; Donskov F; Lee JL; Fraccon A; Pasini F; Porta C; Bowman IA; Bjarnason GA; Ernst DS; Rha SY; Beuselinck B; Hansen A; North SA; Kollmannsberger CK; Wood LA; Vaishampayan UN; Pal SK; Choueiri TK; Heng DYC
Eur Urol Oncol; 2019 Nov; 2(6):643-648. PubMed ID: 31411994
[TBL] [Abstract][Full Text] [Related]
58. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
[TBL] [Abstract][Full Text] [Related]
59. Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities.
Deuker M; Stolzenbach F; Rosiello G; Palumbo C; Martin T; Tian Z; Chun FK; Saad F; Shariat SF; Kapoor A; Karakiewicz PI
J Urol; 2020 Oct; 204(4):671-676. PubMed ID: 32250728
[TBL] [Abstract][Full Text] [Related]
60. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
Singla N; Hutchinson RC; Ghandour RA; Freifeld Y; Fang D; Sagalowsky AI; Lotan Y; Bagrodia A; Margulis V; Hammers HJ; Woldu SL
Urol Oncol; 2020 Jun; 38(6):604.e9-604.e17. PubMed ID: 32253116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
